This brand name is authorized in Austria, Canada, Germany, Estonia, France, Hong Kong, Ireland, Malta, Mexico, Romania, Singapore, Turkey, United Kingdom, South Africa
The drug ALKA-SELTZER contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Acetylsalicylic acid
UNII R16CO5Y76E - ASPIRIN
|
|
Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs. |
|
2
Sodium bicarbonate
UNII 8MDF5V39QO - SODIUM BICARBONATE
|
|
Sodium bicarbonate has antacid properties. Sodium bicarbonate causes neutralisation of gastric acid with the production of carbon dioxide. |
|
3
Citric acid
UNII 2968PHW8QP - CITRIC ACID MONOHYDRATE
|
|
Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| ALKA-SELTZER Effervescent tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02BA01 | Acetylsalicylic acid | N Nervous system → N02 Analgesics → N02B Other analgesics and antipyretics → N02BA Salicylic acid and derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 02152746, 02245367 |
| Country: DE | Bundesinstitut für Arzneimittel und Medizinprodukte | Identifier(s): 04153611 |
| Country: EE | Ravimiamet | Identifier(s): 1003644 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 66725120 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 49258, 49259 |
| Country: HK | Department of Health Drug Office | Identifier(s): 44990 |
| Country: MT | Medicines Authority | Identifier(s): MA639/00901 |
| Country: MX | Comisión Federal para la Protección contra Riesgos Sanitarios | Identifier(s): 17518 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W51368003 |
| Country: SG | Health Sciences Authority | Identifier(s): 08632P |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699546070879 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 31/2.8/0628 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
